vs
MERIT MEDICAL SYSTEMS INC（MMSI）とペナンブラ（PEN）の財務データ比較。上の社名をクリックして会社を切り替えられます
MERIT MEDICAL SYSTEMS INCの直近四半期売上が大きい（$393.9M vs $385.4M、ペナンブラの約1.0倍）。ペナンブラの純利益率が高く（12.3% vs 9.6%、差は2.6%）。ペナンブラの前年同期比売上増加率が高い（22.1% vs 10.9%）。MERIT MEDICAL SYSTEMS INCの直近四半期フリーキャッシュフローが多い（$74.0M vs $68.0M）。過去8四半期でペナンブラの売上複合成長率が高い（17.6% vs 10.3%）
メリットメディカルシステムズ社はグローバルな医療機器メーカーで、心臓病学、放射線学、腫瘍学、内視鏡検査、救命救護の各分野で使用される介入・診断用製品を開発・製造・販売しています。世界中の病院や医療機関に低侵襲のソリューションを提供し、患者の予後改善と診療効率の向上を支援しています。
ペナンブラ社は2004年にArani BoseとAdam Elsesserによって設立された米国の医療機器メーカーで、本社はカリフォルニア州アラメダに所在します。脳卒中や動脈瘤などの血管疾患向けの介入治療用機器の開発・製造を主力事業として展開しています。
MMSI vs PEN — 直接比較
損益計算書 — Q4 2025 vs Q4 2025
| 指標 | | |
|---|---|---|
| 売上 | $393.9M | $385.4M |
| 純利益 | $38.0M | $47.3M |
| 粗利率 | 49.6% | 68.0% |
| 営業利益率 | 13.8% | 15.4% |
| 純利益率 | 9.6% | 12.3% |
| 売上前年比 | 10.9% | 22.1% |
| 純利益前年比 | 36.0% | 40.6% |
| EPS（希薄化後） | $0.64 | $1.20 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $393.9M | $385.4M | ||
| Q3 25 | $384.2M | $354.7M | ||
| Q2 25 | $382.5M | $339.5M | ||
| Q1 25 | $355.4M | $324.1M | ||
| Q4 24 | $355.2M | $315.5M | ||
| Q3 24 | $339.8M | $301.0M | ||
| Q2 24 | $338.0M | $299.4M | ||
| Q1 24 | $323.5M | $278.7M |
| Q4 25 | $38.0M | $47.3M | ||
| Q3 25 | $27.8M | $45.9M | ||
| Q2 25 | $32.6M | $45.3M | ||
| Q1 25 | $30.1M | $39.2M | ||
| Q4 24 | $27.9M | $33.7M | ||
| Q3 24 | $28.4M | $29.5M | ||
| Q2 24 | $35.7M | $-60.2M | ||
| Q1 24 | $28.2M | $11.0M |
| Q4 25 | 49.6% | 68.0% | ||
| Q3 25 | 48.5% | 67.8% | ||
| Q2 25 | 48.2% | 66.0% | ||
| Q1 25 | 48.4% | 66.6% | ||
| Q4 24 | 48.7% | 66.8% | ||
| Q3 24 | 46.4% | 66.5% | ||
| Q2 24 | 47.7% | 54.4% | ||
| Q1 24 | 46.9% | 65.0% |
| Q4 25 | 13.8% | 15.4% | ||
| Q3 25 | 11.1% | 13.8% | ||
| Q2 25 | 12.3% | 12.0% | ||
| Q1 25 | 11.5% | 12.4% | ||
| Q4 24 | 10.3% | 13.6% | ||
| Q3 24 | 11.0% | 11.7% | ||
| Q2 24 | 13.6% | -27.0% | ||
| Q1 24 | 11.1% | 4.3% |
| Q4 25 | 9.6% | 12.3% | ||
| Q3 25 | 7.2% | 12.9% | ||
| Q2 25 | 8.5% | 13.3% | ||
| Q1 25 | 8.5% | 12.1% | ||
| Q4 24 | 7.9% | 10.7% | ||
| Q3 24 | 8.4% | 9.8% | ||
| Q2 24 | 10.6% | -20.1% | ||
| Q1 24 | 8.7% | 3.9% |
| Q4 25 | $0.64 | $1.20 | ||
| Q3 25 | $0.46 | $1.17 | ||
| Q2 25 | $0.54 | $1.15 | ||
| Q1 25 | $0.49 | $1.00 | ||
| Q4 24 | $0.46 | $0.88 | ||
| Q3 24 | $0.48 | $0.75 | ||
| Q2 24 | $0.61 | $-1.55 | ||
| Q1 24 | $0.48 | $0.28 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $446.4M | $186.9M |
| 総負債低いほど良い | $734.0M | — |
| 株主資本純資産 | $1.6B | $1.4B |
| 総資産 | $2.7B | $1.8B |
| 負債/資本比率低いほどレバレッジが低い | 0.46× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $446.4M | $186.9M | ||
| Q3 25 | $392.5M | $321.0M | ||
| Q2 25 | $341.8M | $421.8M | ||
| Q1 25 | $395.5M | $376.1M | ||
| Q4 24 | $376.7M | $324.4M | ||
| Q3 24 | $523.1M | $280.5M | ||
| Q2 24 | $636.7M | $288.3M | ||
| Q1 24 | $581.9M | $223.1M |
| Q4 25 | $734.0M | — | ||
| Q3 25 | $732.9M | — | ||
| Q2 25 | $731.8M | — | ||
| Q1 25 | $730.7M | — | ||
| Q4 24 | $729.6M | — | ||
| Q3 24 | $750.5M | — | ||
| Q2 24 | $801.3M | — | ||
| Q1 24 | $800.1M | — |
| Q4 25 | $1.6B | $1.4B | ||
| Q3 25 | $1.5B | $1.4B | ||
| Q2 25 | $1.5B | $1.3B | ||
| Q1 25 | $1.4B | $1.2B | ||
| Q4 24 | $1.4B | $1.2B | ||
| Q3 24 | $1.3B | $1.1B | ||
| Q2 24 | $1.3B | $1.2B | ||
| Q1 24 | $1.2B | $1.2B |
| Q4 25 | $2.7B | $1.8B | ||
| Q3 25 | $2.6B | $1.7B | ||
| Q2 25 | $2.6B | $1.7B | ||
| Q1 25 | $2.5B | $1.6B | ||
| Q4 24 | $2.4B | $1.5B | ||
| Q3 24 | $2.4B | $1.5B | ||
| Q2 24 | $2.4B | $1.5B | ||
| Q1 24 | $2.3B | $1.6B |
| Q4 25 | 0.46× | — | ||
| Q3 25 | 0.48× | — | ||
| Q2 25 | 0.49× | — | ||
| Q1 25 | 0.51× | — | ||
| Q4 24 | 0.53× | — | ||
| Q3 24 | 0.57× | — | ||
| Q2 24 | 0.62× | — | ||
| Q1 24 | 0.65× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $98.5M | $86.5M |
| フリーキャッシュフロー営業CF - 設備投資 | $74.0M | $68.0M |
| FCFマージンFCF / 売上 | 18.8% | 17.7% |
| 設備投資強度設備投資 / 売上 | 6.2% | 4.8% |
| キャッシュ転換率営業CF / 純利益 | 2.59× | 1.83× |
| 直近12ヶ月FCF直近4四半期 | $215.7M | $174.9M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $98.5M | $86.5M | ||
| Q3 25 | $75.0M | $58.3M | ||
| Q2 25 | $83.3M | $44.9M | ||
| Q1 25 | $40.6M | $49.0M | ||
| Q4 24 | $68.7M | $51.1M | ||
| Q3 24 | $47.3M | $56.5M | ||
| Q2 24 | $68.5M | $22.6M | ||
| Q1 24 | $36.2M | $38.3M |
| Q4 25 | $74.0M | $68.0M | ||
| Q3 25 | $52.5M | $42.0M | ||
| Q2 25 | $69.6M | $29.4M | ||
| Q1 25 | $19.5M | $35.5M | ||
| Q4 24 | $65.3M | $45.7M | ||
| Q3 24 | $38.0M | $51.0M | ||
| Q2 24 | $57.9M | $18.1M | ||
| Q1 24 | $24.5M | $32.5M |
| Q4 25 | 18.8% | 17.7% | ||
| Q3 25 | 13.7% | 11.8% | ||
| Q2 25 | 18.2% | 8.7% | ||
| Q1 25 | 5.5% | 11.0% | ||
| Q4 24 | 18.4% | 14.5% | ||
| Q3 24 | 11.2% | 16.9% | ||
| Q2 24 | 17.1% | 6.0% | ||
| Q1 24 | 7.6% | 11.7% |
| Q4 25 | 6.2% | 4.8% | ||
| Q3 25 | 5.8% | 4.6% | ||
| Q2 25 | 3.6% | 4.6% | ||
| Q1 25 | 5.9% | 4.2% | ||
| Q4 24 | 1.0% | 1.7% | ||
| Q3 24 | 2.8% | 1.8% | ||
| Q2 24 | 3.1% | 1.5% | ||
| Q1 24 | 3.6% | 2.1% |
| Q4 25 | 2.59× | 1.83× | ||
| Q3 25 | 2.70× | 1.27× | ||
| Q2 25 | 2.56× | 0.99× | ||
| Q1 25 | 1.35× | 1.25× | ||
| Q4 24 | 2.46× | 1.52× | ||
| Q3 24 | 1.66× | 1.91× | ||
| Q2 24 | 1.92× | — | ||
| Q1 24 | 1.28× | 3.48× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
MMSI
| Other | $154.6M | 39% |
| Peripheral Intervention | $93.2M | 24% |
| Cardiac Intervention | $50.2M | 13% |
| OEM | $42.6M | 11% |
| Custom Procedural Solutions | $33.1M | 8% |
| Endoscopy Segment | $20.1M | 5% |
PEN
セグメントデータなし
